Bio-Path Holdings, Inc. (BPTH) Income Statement
BPTH 2024 at a glance
Fiscal year ended December 31, 2024 · U.S. dollarsBPTH revenue and net income
BPTH profit margins
BPTH growth rates
to 2024| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BPTH quarterly EPS vs estimates
Bio-Path beat the analyst EPS estimate in 4 of the last 8 quarters.
BPTH income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $37,000 | $13,000 | $0 |
| Cost of revenue | — | $178,000 | $178,000 | $161,000 | $151,000 | $230,000 | $426,000 | $8.6M | $8.3M | $201,762 |
| Gross profit | — | −$178,000 | −$178,000 | −$161,000 | −$151,000 | −$230,000 | −$426,000 | $37,000 | $13,000 | −$201,762 |
| Research & development | $7.3M | $11.6M | $9.2M | $5.9M | $6.6M | $4.6M | $4.6M | $5.5M | $5.5M | $3.0M |
| Sales, general & admin | $4.7M | $4.2M | $4.7M | $4.5M | $4.3M | $4.1M | $3.4M | $3.5M | $3.0M | $2.5M |
| Total operating expenses | $12.0M | $15.8M | $13.9M | $10.4M | $10.9M | $8.7M | $8.0M | $9.0M | $8.5M | $5.5M |
| Operating income | −$12.0M | −$15.8M | −$13.9M | −$10.4M | −$10.9M | −$8.7M | −$8.6M | −$9.0M | −$8.5M | −$5.5M |
| Interest income | $14,000 | $52,000 | $33,000 | $3,000 | $26,000 | $94,000 | $7,000 | $9,000 | $12,000 | $17,670 |
| Interest expense | — | — | $33,000 | $3,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | −$9.9M | −$16.1M | −$13.9M | −$10.4M | −$10.9M | −$8.6M | −$8.6M | −$7.0M | −$6.8M | −$5.5M |
| Income taxes | — | — | −$33,000 | −$3,000 | −$26,000 | −$94,000 | −$608,000 | −$1.9M | −$1.7M | $0 |
| Net income | −$9.9M | −$16.1M | −$13.8M | −$10.4M | −$10.9M | −$8.5M | −$8.6M | −$7.0M | −$6.8M | −$5.5M |
| EBITDA | −$11.8M | −$15.8M | −$13.7M | −$10.3M | −$10.7M | −$8.5M | −$6.9M | −$10.5M | −$10.0M | −$5.3M |
| EPS (diluted) | −$6.81 | −$37.25 | −$28.12 | −$20.19 | −$45.57 | −$34.62 | −$26.18 | −$240.20 | −$244.00 | −$128.00 |
| Gross margin | — | — | — | — | — | — | — | 100.0% | 100.0% | — |
| Operating margin | — | — | — | — | — | — | — | −24,232.4% | −65,192.3% | — |
| Net margin | — | — | — | — | — | — | — | −18,981.1% | −51,923.1% | — |
| Mar '26 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $274,000 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | $32,000 | $47,000 | $41,000 | $46,000 | $46,000 | $45,000 |
| Gross profit | — | — | — | — | — | — | −$32,000 | −$47,000 | $233,000 | −$46,000 | −$46,000 | −$45,000 |
| Research & development | $38,000 | $275,000 | $4.0M | $2.0M | $1.8M | $1.3M | $1.9M | $2.3M | $2.3M | $2.3M | $3.1M | $4.0M |
| Sales, general & admin | $259,000 | $213,000 | $514,000 | $1.3M | $808,000 | $1.3M | $1.2M | $1.4M | $757,000 | $984,000 | $1.2M | $1.3M |
| Total operating expenses | $297,000 | $488,000 | $4.6M | $3.2M | $2.6M | $2.6M | $3.0M | $3.6M | $3.0M | $3.3M | $4.2M | $5.3M |
| Operating income | −$297,000 | −$488,000 | −$4.6M | −$3.2M | −$2.6M | −$2.6M | −$3.0M | −$3.7M | −$3.0M | −$3.3M | −$4.2M | −$5.3M |
| Interest income | — | — | — | — | $4,000 | $4,000 | $6,000 | $0 | $4,000 | $5,000 | $8,000 | $19,000 |
| Interest expense | $25,000 | $130,000 | $35,000 | $5,000 | — | — | — | $0 | $19,000 | — | — | $19,000 |
| Income before taxes | −$270,000 | −$976,000 | −$4.6M | −$2.9M | −$2.8M | −$2.1M | −$1.9M | −$3.2M | −$3.4M | −$3.2M | −$4.2M | −$5.3M |
| Income taxes | — | — | — | — | — | — | — | $3,724 | $339,000 | −$77,000 | −$76,085 | −$19,000 |
| Net income | −$270,000 | −$976,000 | −$4.6M | −$2.9M | −$2.8M | −$2.1M | −$1.9M | −$3.2M | −$3.4M | −$3.2M | −$4.2M | −$5.3M |
| EBITDA | −$234,000 | −$839,000 | −$4.5M | −$2.8M | −$2.6M | −$2.6M | −$3.0M | −$3.6M | −$3.0M | −$3.3M | −$4.2M | −$5.2M |
| EPS (diluted) | — | — | −$0.55 | −$0.40 | −$0.07 | −$0.70 | −$1.16 | −$4.88 | −$7.05 | −$6.40 | −$10.60 | −$13.20 |
| Gross margin | — | — | — | — | — | — | — | — | 85.0% | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — | −1,106.9% | — | — | — |
| Net margin | — | — | — | — | — | — | — | — | −1,230.7% | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BPTH's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BPTH financial results
Bio-Path reported no revenue in fiscal year 2024 (ended December 31, 2024). It had a net loss of $9.9 million. Diluted earnings per share came to −$6.81.
See the BPTH stock overview for the latest quote and news, or the BPTH chart for price history and technical indicators.
BPTH income statement FAQ
Does Bio-Path have revenue?
Bio-Path reported no revenue for fiscal year 2024, which ended on December 31, 2024.
Is Bio-Path profitable?
No. Bio-Path reported a net loss of $9.9 million in fiscal 2024.
How much does Bio-Path spend on research and development?
Bio-Path spent $7.3 million on research and development in fiscal 2024.
What are Bio-Path's earnings per share?
Bio-Path earned $-6.81 per diluted share in fiscal 2024, compared with $-37.25 a year earlier.
When does Bio-Path's fiscal year end?
Bio-Path's fiscal year ends in December. The latest annual report covers the year ended December 31, 2024.